MIM
DMRA

MetLife Investment Management’s Damora Therapeutics DMRA Stock Holding History

MetLife Investment Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$819K Buy
+31,499
New +$763K ﹤0.01% 1627

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

MetLife Investment Management's DMRA Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Damora Therapeutics (DMRA) in Q2 2026: 31,499 shares worth $819K. The stake represents ﹤0.01% of the portfolio and ranks #1627 among its holdings.

104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • MetLife Investment Management held 31,499 shares of Damora Therapeutics worth $819K as of Q2 2026.
  • Damora Therapeutics was a new MetLife Investment Management position in Q2 2026.
  • Damora Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1627 holding.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.